Challenges in cancer molecular targets and therapeutics

Frontiers in Oncology

Volumn 1, Issue MAY, 2011, Pages

  Wang, Yisong ^a   Giaccone, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882782812     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2011.00004     Document Type: Article

References (24)

1. Astsaturov, I., Ratushny, V., Sukhanova, A., Einarson, M. B., Bagnyukova, T., Zhou, Y., Devarajan, K., Silverman, J. S., Tikhmyanova, N., Skobeleva, N., Pecherskaya, A., Nasto, R. E., Sharma, C., Jablonski, S. A., Serebriiskii, I. G., Weiner, L. M., and Golemis, E. A. (2010). Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Sci. Signal. 3, ra67.
2. Baselga, J., Norton, L., Albanell, J., Kim, Y. M., and Mendelsohn, J. (1998). Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58, 2825-2831.
3. Borovski, T., De Sousa, E. M. F., Vermeulen, L., and Medema, J. P. (2011). Cancer stem cell niche: the place to be. Cancer Res. 71, 634-639.
4. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C. L. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037.
5. Erkizan, H. V., Kong, Y., Merchant, M., Schlottmann, S., Barber-Rotenberg, J. S., Yuan, L., Abaan, O. D., Chou, T. H., Dakshanamurthy, S., Brown, M. L., Uren, A., and Toretsky, J. A. (2009). A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat. Med. 15, 750-756.
6. Gorczynski, M. J., Grembecka, J., Zhou, Y., Kong, Y., Roudaia, L., Douvas, M. G., Newman, M., Bielnicka, I., Baber, G., Corpora, T., Shi, J., Sridharan, M., Lilien, R., Donald, B. R., Speck, N. A., Brown, M. L., and Bushweller, J. H. (2007). Allosteric inhibition of the protein-protein interaction between the leukemia-associated proteins Runx1 and CBFbeta. Chem. Biol. 14, 1186-1197.
7. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., and Sawyers, C. L. (2001). Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880.
8. Hahn, W. C., and Weinberg, R. A. (2002). Modelling the molecular circuitry of cancer. Nat. Rev. Cancer 2, 331-341.
9. Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
10. Hartman, J. L. IV, Garvik, B., and Hartwell, L. (2001). Principles for the buffering of genetic variation. Science 291, 1001-1004.
11. Jones, K. L., and Buzdar, A. U. (2009). Evolving novel anti-HER2 strategies. Lancet Oncol. 10, 1179-1187.
12. Kaelin, W. G. Jr. (2005). The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5, 689-698.
13. Konopleva, M. Y., and Jordan, C. T. (2011). Leukemia stem cells and microenvironment: biology and therapeutic targeting. J. Clin. Oncol. 29, 591-599.
14. Kuiken, H. J., and Beijersbergen, R. L. (2010). Exploration of synthetic lethal interactions as cancer drug targets. Future. Oncol. 6, 1789-1802.
15. Lucchesi, J. C. (1968). Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanogaster. Genetics 59, 37-44.
16. Luo, J., Solimini, N. L., and Elledge, S. J. (2009). Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823-837.
17. Rajkumar, S. V., Richardson, P. G., Hideshima, T., and Anderson, K. C. (2005). Proteasome inhibition as a novel therapeutic target in human cancer. J. Clin. Oncol. 23, 630-639.
18. Saito, Y., Uchida, N., Tanaka, S., Suzuki, N., Tomizawa-Murasawa, M., Sone, A., Najima, Y., Takagi, S., Aoki, Y., Wake, A., Taniguchi, S., Shultz, L. D., and Ishikawa, F. (2010). Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat. Biotechnol. 28, 275-280.
19. Sheikh, K. D., Banerjee, P. P., Jagadeesh, S., Grindrod, S. C., Zhang, L., Paige, M., and Brown, M. L. (2010). Fluorescent epigenetic small molecule induces expression of the tumor suppressor ras-association domain family 1A and inhibits human prostate xenograft. J. Med. Chem. 53, 2376-2382.
20. Tennant, D. A., Duran, R. V., and Gottlieb, E. (2010). Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer 10, 267-277.
21. Trepel, J., Mollapour, M., Giaccone, G., and Neckers, L. (2010). Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer 10, 537-549.
22. Warburg, O. (1923). Metabolism of tumors. Biochem. Z. 142, 371-333.
23. Whitesell, L., and Lindquist, S. L. (2005). HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 5, 761-772.
24. Zhou, B. B., Zhang, H., Damelin, M., Geles, K. G., Grindley, J. C., and Dirks, P. B. (2009). Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 8, 806-823.